Ribomic's wet AMD candidate shows positive phase 1/2a topline results
A single dose of RBM-007, an oligonucleotide-based aptamer with anti-FGF2 activity, showed positive topline results in a phase 1/2a clinical trial in wet age-related macular degeneration patients, according to a press release.
RBM-007 (Ribomic) was well-tolerated and had no dose-limiting toxicities or systemic or ocular serious adverse events, and seven of nine patients treated showed evidence of RBM-007 bioactivity.
The open-label, dose escalation SUSHI study included nine subjects who had previously received anti-VEGF treatments. Subjects received a single injection of RBM-007 in three sequential dose cohorts, the release said.
“[The] SUSHI study has demonstrated that [a] single dose of intravitreal RBM-007 up to 2 mg dose is well-tolerated in subjects with wet AMD. We are pleased to demonstrate evidence of clinical efficacy in several subjects as measured by BCVA and OCT thickness, suggesting FGF2 is an important target in the pathogenesis of wet AMD,” Yusuf Ali, PhD, CEO of Ribomic USA, said in the release.